Lucentis
ApprovedSmall molecule
NovartisLucentis is one of 139 small molecule programs targeting Choroidal Neovascularization. It is currently in Approved.
8
Indications
44
Total Trials
2
Active Trials
138
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
237 competitors in Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Lucentis
RochePhase 3
Eylea
RegeneronPhase 3
Vabysmo
RochePhase 3
Beovu
NovartisPhase 3
Macugen
PfizerPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Lucentis
NovartisApproved
Retaane
AAlcon Research
Phase 3
Forzinity
SStealth BioTherapeutics Inc.
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diabetic Macular Edema8 trials
Show 5 more trials
Macular Degeneration6 trials
Show 3 more trials
Age-Related Macular Degeneration6 trials
Show 3 more trials
Neovascular AMD4 trials
Wet AMD3 trials
13 more indications
Proliferative Diabetic Retinopathy3 trials
Efficacy and Safety2 trials
Itching1 trial
Treatment1 trial
Combination Therapy1 trial
Choroidal Neovascularization1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lucentis. EMBL-EBI & Wellcome Sanger Institute.
- [4]